Curia Sustainability Profile
Curia Global, commonly referred to as Curia, is a leading contract research, development, and manufacturing organisation headquartered in the United States. Established in 2019, Curia has rapidly expanded its operational footprint across North America and Europe, positioning itself as a key player in the pharmaceutical and biotechnology sectors. Specialising in drug development and manufacturing, Curia offers a comprehensive suite of services, including analytical testing, formulation development, and commercial manufacturing. What sets Curia apart is its commitment to quality and innovation, ensuring that clients receive tailored solutions that meet stringent regulatory standards. With a strong market presence, Curia has achieved significant milestones, including strategic acquisitions that enhance its capabilities. The company is recognised for its expertise in complex drug modalities, making it a trusted partner for clients seeking to navigate the complexities of drug development.
DitchCarbon Score
How does Curia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Curia's score of 35 is higher than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Curia's reported carbon emissions
In 2021, Curia Global, Inc. reported total carbon emissions of approximately 41,290,410 kg CO2e from Scope 1 and about 46,508,720 kg CO2e from Scope 2, totalling around 87,799,130 kg CO2e. The company has not disclosed any Scope 3 emissions data. Curia is committed to achieving net-zero emissions across all scopes by 2050, with a near-term target status of "Committed" as of June 2024. This commitment aligns with the Science Based Targets initiative (SBTi), which underscores the company's dedication to addressing climate change within the pharmaceuticals, biotechnology, and life sciences sector. Curia's emissions data is not cascaded from any parent organisation, indicating that these figures are independently reported. The company continues to focus on reducing its carbon footprint while adhering to industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | |
|---|---|
| Scope 1 | 41,290,410 |
| Scope 2 | 46,508,720 |
| Scope 3 | - |
How Carbon Intensive is Curia's Industry?
How Carbon Intensive is Curia's Location?
Curia's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Curia has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Pharmaceutical Product Development, LLC
Frequently Asked Questions
Common questions about Curia's sustainability data and climate commitments